Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
Executive Summary
Industry dismay at slow pace of ANDA approvals and FDA communications in early years of first user fee agreement factored into GDUFA II negotiations.
You may also be interested in...
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Legislation would create a potential second priority review pathway for generics, as well as another priority review voucher program, but may not be as enticing as GDUFA II proposal.
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Legislation would create a potential second priority review pathway for generics, as well as another priority review voucher program, but may not be as enticing as GDUFA II proposal.
FDA Aims To 'Pierce The Rhetoric' On Generic Application Backlog
ANDA backlog is now largely cleared, FDA's Uhl notes, 'and in many cases we've actually gone above and beyond our negotiated commitments in order to really meet the stakeholder expectations.'